Imaging of Prostate-Specific Membrane Antigen Using [¹⁸F]DCFPyL.

Area of Science:

• Nuclear medicine
• Radiochemistry
• Oncology

Background:

• Prostate-specific membrane antigen (PSMA) is a target for imaging cancers expressing it in neovasculature.
• Radiotracers using positron-emitting radionuclides like Fluorine-18 (18F) are of significant interest for molecular imaging.
• The small molecule PSMA inhibitor [18F]DCFPyL shows initial success in targeting PSMA.

Purpose of the Study:

• To review the literature on the radiotracer [18F]DCFPyL.
• To summarize radiosynthetic approaches for [18F]DCFPyL.
• To present preclinical and clinical data on the utility of [18F]DCFPyL.

Main Methods:

• Literature review of studies involving [18F]DCFPyL.
• Analysis of radiosynthetic methods for radiolabeling.
• Compilation of preclinical experimental data.
• Review of clinical evidence for diagnostic applications.

Main Results:

• [18F]DCFPyL has demonstrated initial success as a PSMA-targeted radiotracer.
• Various radiosynthetic strategies have been developed for its preparation.
• Preclinical data support its potential in imaging.
• Clinical utility is being established for prostate cancer and clear cell renal cell carcinoma.

Conclusions:

• [18F]DCFPyL is a valuable radiotracer for PSMA-targeted molecular imaging.
• Its application extends to both prostate cancer and clear cell renal cell carcinoma.
• Further clinical evaluation is ongoing to define its full diagnostic role.